From my perspective, RVX doesn't have the internal clinical-science experience to take ABL forward from here. The company is too dependent on external consultants, who have many other commitments and priorities. The drug is too big for RVX to handle. It has to be a job for a major BP.

RVX owes it to patients, medical science, and investors to let someone else take over. It could be a buyout or a partnership. But in my view they should definitely not go it alone. It's not just a question of money. It's one of experience and expertise so as to avoid more errors and wasted time.

Thank goodness the people developing drugs, antibodies, and vaccines for covid haven't been moving at Don's pace! To think what they have achieved while he's been having his "very promising ongoing discussions".